$CUR - Neuralstem, Inc. Has Added A News Video And News Article To Its Website.
Biotech, Long Only
Seeking Alpha Analyst Since 2012
DO NOT INVEST ON THE BASIS OF MY OPINIONS
Independent writer/trader/investor that tends to write more for informational purposes than to advance a particular trading position. My positions can change dramatically as new information comes to my attention. All stocks are risky. Please, don't follow me into a penny stock without realizing they are HIGHLY risky and you can lose ALL of your investment. No payment in any form is accepted for my writing by any company or other party. I only receive that which comes from writing on Seeking Alpha.
I’M NOT A FINANCIAL ADVISOR, ATTORNEY, OR SCIENTIST & ONLY GIVE MY OPINIONS. SEEK EXPERT ADVICE ELSEWHERE. ;)
Investment Philosophy: Understand why you are getting in.
Please click to follow me if you like my work. There’s an option to do so at the top of my articles. Best functionality of site is on desktop.
Education is an undergraduate degree in Business Administration and Management. Masters' in Organizational Management.
Be kinder than necessary, for everyone you meet is fighting some kind of battle. ;)
$CUR - Neuralstem, Inc. has added a news video and news article to its website.
Titles:
Stem cell trial seeks longer lives for victims of deadly ALS
Neuralstem: Sizing Up Potential Key Events of 2014
Date: 9-JAN-2014, Article and News Video Date: 8-JAN-2014
NSI-566/ALS Emory University Site Principal Investigator, Jonathan D. Glass, M.D., and Phase II patient, April Moundzouris, are featured in a video news story by Reuters' Ben Gruber. Former biotech/pharma analyst, Larry Smith, analyzes the progress and potential key events in the year ahead for Neuralstem's NSI-566 and NSI-189, in an expansive article.
To view this news coverage, click here: http://www.neuralstem.com/neuralstem-in-the-news
Disclosure: I am long CUR, .
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.